Clinical Trial Update: Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants

View source ↗

Summary

GSK-sponsored COPD trial evaluating triple therapy has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Status: COMPLETED | Results posted: 2025-08-17